Shockwave Medical Study Confirms Benefit of IVL-First Strategy in Real-World Female Patients with Complex Calcified Lesions in Late-Breaking Data Presentation at EuroPCR 2025
PARIS, May 20, 2025 /PRNewswire/ -- Shockwave Medical, Inc., part of Johnson & Johnson MedTech and a global leader in the field of circulatory restoration, announced today the 30-day primary endpoint results of EMPOWER CAD, the first prospective, real-world percutaneous coronary intervention (PCI) study in female patients with complex, calcified coronary artery disease. The favorable results confirm the results of earlier retrospective analyses demonstrating the benefits of coronary intravascular lithotripsy (IVL) in female patients. The results were presented in a late-breaking presentation at the annual EuroPCR meeting in Paris.
Women with coronary artery calcification (CAC) undergoing PCI are often underrepresented in clinical trials and have historically poorer outcomes than men, including increased risk of adverse clinical outcomes and high rates of procedural complications with other calcium modification treatments, such as rotational or orbital atherectomy.1,2
Investigators designed the EMPOWER CAD study to evaluate real-world outcomes in female patients with severely calcified coronary lesions treated with an IVL-first treatment strategy and confirm positive results from previous studies showing similar safety and effectiveness outcomes across both men and women. EMPOWER CAD is a pivotal study comprised of a series of firsts: Shockwave's first prospective, post-market study of IVL examining an all-comers female population with minimal exclusion criteria, the first study to encourage a Shockwave IVL-first PCI strategy for calcified coronary lesions, and the first study to follow-up with enrolled patients for three years following IVL therapy.
The study enrolled 399 participants across 45 sites spanning five countries in the European Union and United States. The study is led by co-principal investigators Margaret McEntegart, M.D., Ph.D., Director of the Complex PCI and CTO programs and Cardiac Catheterization Labs at Columbia University Medical Center/NewYork-Presbyterian Hospital and Alexandra Lansky, M.D., Professor of Medicine in the section of Cardiovascular Medicine and Director, Heart and Vascular Clinical Research Program, Yale University School of Medicine. The study's European lead is Nieves Gonzalo, M.D., Ph.D., consultant interventional cardiologist at Hospital Clinico San Carlos in Madrid, Spain.†
"Women are typically underdiagnosed, underrepresented and have underwhelming outcomes in coronary artery disease studies," said Dr. Lansky. "Our goal with the EMPOWER CAD study was to address this gap and determine whether Shockwave IVL should be considered as the front-line calcium modification approach in female patients with complex coronary artery disease. The results demonstrate the benefits of IVL use in this specific patient population and validate findings from previous studies."
The primary effectiveness endpoint of procedural success, defined as stent delivery with ≤30% residual stenosis for all treated target lesions without in-hospital target lesion failure (TLF), was 86.9% at 30 days. The primary safety endpoint, defined as TLF as a composite of cardiac death, myocardial infarction attributable to target vessel (TV-MI) or ischemia-driven target lesion revascularization (ID-TLR) within 30 days, was 12.1%. TLF was primary driven by the rate of periprocedural MI3 (10.6%); the majority of these periprocedural MIs were not associated with any clinical signs or symptoms. Cardiac death and ID-TLR rates were each 1.3%. Procedural complications were rare with only one patient (0.2%) having a serious angiographic complication when assessed at the end of the procedure. There were also clinically and statistically significant improvements in health-related quality of life scores at 30 days compared to baselines.
"By leveraging a Shockwave IVL-first approach, the EMPOWER CAD 30-day results demonstrated high procedural success, low complication rates and significant improvements in quality of life among real-world female patients," said Dr. McEntegart. "While we look forward to following these patients for the next three years, these primary endpoint results confirm that excellent outcomes can be achieved with the use of Shockwave IVL in women with complex, calcified coronary artery disease."
Nick West., M.D., Chief Medical Officer, Shockwave Medical, emphasized the significance of the EMPOWER CAD study, stating, "Today marks a critical milestone in the journey to improve outcomes for female patients with calcified lesions. What began as an idea a few years ago is now a commendable reality today, thanks to study leadership and site investigators accelerating completion and reporting these important results. We're looking forward to learning more about the benefits of IVL therapy in this underrepresented patient population, both acutely and at extended follow-up."
About Shockwave MedicalShockwave Medical, Inc., part of Johnson & Johnson MedTech, is a leader in the development and commercialization of innovative products that are transforming the treatment of cardiovascular disease. Its first-of-its-kind Intravascular Lithotripsy (IVL) technology has transformed the treatment of atherosclerotic cardiovascular disease by safely using sonic pressure waves to disrupt challenging calcified plaque, resulting in significantly improved patient outcomes. Its Reducer technology, which is under clinical investigation in the United States and is CE Marked in the European Union and the United Kingdom, is designed to provide relief to the millions of patients worldwide suffering from refractory angina by redistributing blood flow within the heart. Learn more at www.shockwavemedical.com.
Cardiovascular Solutions from Johnson & Johnson MedTechAcross Johnson & Johnson, we are tackling the world's most complex and pervasive health challenges. Through a cardiovascular portfolio that provides healthcare professionals with advanced mapping and navigation, miniaturized tech, and precise ablation, we are addressing conditions with significant unmet needs such as heart failure, coronary artery disease, stroke, and atrial fibrillation. We are the global leaders in heart recovery, circulatory restoration and the treatment of heart rhythm disorders, as well as an emerging leader in neurovascular care, committed to taking on two of the leading causes of death worldwide in heart failure and stroke.
About Johnson & JohnsonAt Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow and profoundly impact health for humanity. Learn more about our MedTech sector's global scale and deep expertise in cardiovascular, orthopaedics, surgery and vision solutions at https://thenext.jnjmedtech.com. Follow us at @JNJMedTech and on LinkedIn. Shockwave Medical, Inc. is part of Johnson & Johnson MedTech.
Cautions Concerning Forward-Looking StatementsThis press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Shockwave Medical, Inc. and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to: uncertainty of commercial success; challenges to patents; competition, including technological advances, new products and patents attained by competitors; manufacturing difficulties and delays; product efficacy or safety concerns resulting in product recalls or regulatory action; changes to applicable laws and regulations, including global health care reforms; changes in behavior and spending patterns of purchasers of health care products and services; and trends toward healthcare cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's most recent Annual Report on Form 10-K, including in the sections captioned "Cautionary Note Regarding Forward-Looking Statements" and "Item 1A. Risk Factors," and in Johnson & Johnson's subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. Neither Shockwave Medical, Inc. nor Johnson & Johnson undertakes to update any forward-looking statement as a result of new information or future events or developments.as a result of new information or future events or developments.
† Drs. McEntegart, Lansky and Gonzalo are paid consultants of Shockwave Medical. They have not been compensated in connection with this press release.
1 Giustino et al., JACC Cardiovasc Int 2016; Ford et al., Catheter Cardiovasc Interv 2020; Hussain et al., JSCAI 2022.2 Kim et al. Catheter Cardiovasc Interv. 20163 As defined by SCAI for periprocedural MI and Fourth Universal (Type 4a) for spontaneous MI beyond discharge.
Media Contacts: Lindsey Diaz-MacInnisldiazmac@its.jnj.com
Rachael Jarnaginrjarnagi@its.jnj.com
Investor Contact:Sandra Easton Investor-relations@its.jnj.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/shockwave-medical-study-confirms-benefit-of-ivl-first-strategy-in-real-world-female-patients-with-complex-calcified-lesions-in-late-breaking-data-presentation-at-europcr-2025-302459685.html
SOURCE Johnson & Johnson MedTech
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
National Geographic
an hour ago
- National Geographic
We may finally solve the mystery of the shipwreck that lies beneath Ground Zero
The Museum of the City of New York is launching a new investigation into the remains of a vessel found beneath lower Manhattan during subway construction in 1916. Museum of the City of New York curator William M. Williamson and historian James A. Kelly examine timbers, possibly from the Tyger, on view in a 1954 exhibition Shipyards of New York. Photograph Courtesy Museum of the City of New York A shipwreck mystery buried under Ground Zero could soon be solved, with scientists set to investigate whether a doomed 17th-century vessel—captained by a Dutch explorer who settled Manhattan—lies deep beneath the former Twin Towers. Visitors flock to the World Trade Center site to see its 9/11 memorial and museum, and honor victims of the 2001 terrorist attack. But few would know Ground Zero was once nothing but ocean, before land reclamation expanded Manhattan, and that it hides clues to one of New York's oldest enigmas, which is linked to this year's 400th anniversary of the city's founding. Generations of U.S. and European researchers have attempted to locate a long-lost Dutch ship called the Tyger. It helped the Netherlands map America's northeast coast, and paved the way for New York's colonization by the Dutch, before it sank in 1613 roughly where the Twin Towers later stood. In the century after the Tyger disappeared, first the Dutch and then the British needed greater space to expand their Manhattan settlements. So they dumped dirt and garbage into the surrounding rivers, which created new land, and expanded lower Manhattan until buildings covered the location where the Tyger sank. Now the Museum of the City of New York (MCNY) is launching its first-ever major investigation to try to find out whether a shipwreck beneath Ground Zero, unearthed in 1916 during construction of a subway line, is indeed the Tyger. Its tests will focus on eight feet of ship keel and ribs unearthed in that dig, says Margaret Connors McQuade, MCNY Director of Collections. The earliest known map of New Amsterdam, circa 1639, showing Manhattan, Staten Island, Fort Amsterdam, Brooklyn, the Bronx, plantations, windmills, and Native American villages. Photograph by Everett Collection/Bridgeman Images To determine the age and origin of these timber artifacts, the museum's researchers may use tree species identification, analysis of chemical signatures in the wood, and examination of tree ring patterns. 'The quest to confirm the Tyger's identity is not just a scientific endeavor, it is a journey into the city's earliest days,' explains MCNY President Stephanie Hill Wilchfort. MCNY curatorial and collections staff will collaborate with outside experts in the fields of marine archeology and dendrochronology, including Martijn Manders, Founding Head of the Maritime Programme, Cultural Heritage Agency of the Netherlands, and Marta Domínguez Delmás, Senior Researcher at the Cultural Heritage Agency of the Netherlands. How the Dutch came to control Manhattan New York as we know it may never have existed if not for the Tyger and its captain Adriaen Block, historians say. He mapped the area for the Dutch, and then in 1614 became the first European to settle what is now Manhattan, which at the time was inhabited by the Lenape tribe (whose language gave the island its present-day name). Yet Block is a curiously anonymous figure in New York. The city has no statue of him, only a bronze plaque at 45 Broadway, which details how Block built Manhattan's first European settlement on behalf of the Dutch. In the 1600s, at the time of Block's arrival, the Netherlands was a maritime superpower, competing with Spain, Portugal and Britain to 'discover' and colonize lands the world over. Spearheading its global expansion were captains like Block. Between 1611 and 1614, he led four voyages to the Hudson River region, which now encompasses New York City, says McQuade. Several of these expeditions were on board the Tyger. In the process, Block charted many waterways from New Jersey north to Cape Cod, including near Rhode Island's Block Island, which is named after him and has become a popular summer getaway. 'His cartographic work corrected key geographic misconceptions and laid the groundwork for future Dutch colonization in the region,' McQuade says. (Was Manhattan really sold to the Dutch for just $24?) Block also cataloged geography and natural resources, and this information convinced the Dutch that Manhattan was ripe for settlements. So, in 1614, Block came ashore at southern Manhattan and built four houses. This outpost grew over the course of several decades into New Amsterdam, part of a Dutch colony called New Netherland, which soon covered parts of what are now New York, New Jersey, Maryland, Pennsylvania, Connecticut, and Delaware. It wasn't until 1664, when the English seized Manhattan, that New York became its name. Timbers thought to be from the Tyger, on display at the Marine Gallery. Photograph Courtesy Museum of the City of New York After losing the Tyger to fire, Captain Adriaen Block constructed the "Onrust" with the help of the Lenape, depicted up in an illustration for Old Times in the Colonies by Charles Carleton Coffin. Photograph by Look and Learn/Bridgeman Images By then the Dutch had already built Fort Amsterdam, next to what is now The Battery, under the leadership of colonial governor Peter Minuit. New York may not have been founded by the Dutch in the 1620s if not for Block, says Jaap Jacobs, Dutch historian and expert on Dutch exploration of North America. Thanks to Block's detailed charting of the waters surrounding New York, the Dutch were able to create maps which let them gain a monopoly on shipping in this area. 'Without this development, the subsequent colonization by the Dutch West India Company from 1623 onwards would have been much more difficult,' Jacobs says. 'It may not have yielded the same result: the founding of New Amsterdam, and New York, in the 1620s.' (Colonial New York was rowdy, filthy, smelly) Tyger, Tyger, burning bright But when Block settled Manhattan in 1614, he was not sailing the Tyger, because that ship had sunk a few months earlier, McQuade says. The Tyger vanished after it caught fire accidentally while anchored in seas roughly where Ground Zero now stands. Three centuries then passed without any sign of the vessel. Then, in 1916, charred shipwreck timber was unearthed during subway construction at the corner of Greenwich and Dey streets, which now adjoins Ground Zero. 'Along with the timbers, they uncovered a Dutch broad-headed axe, trade beads, clay pipes, a length of chain, a small canon, and shards of blue and white pottery,' McQuade says. (When Henry Hudson first looked on Manhattan, what did he see?) At the time, amateur historian James A. Kelly swiftly reported these findings to several museums. It is possible that more remnants from that shipwreck are still buried beneath Ground Zero. Because the damaged vessel was never properly excavated, only a section of its keel and ribs were saved, McQuade says. Those timber artifacts spent decades gathering dust, first at the New York Aquarium and then at MCNY. But in 1955, fresh research supported the theory those materials came from the Tyger, McQuade says. Radiocarbon dating by Columbia University traced the timber to between 1595 and 1635, while an iron bolt from the same shipwreck was found to have been made about 1600 using a European smelting process. All of which hinted that the remains unearthed at Ground Zero may be from the Tyger. Yet it did not amount to proof. This 1651 engraving by Kryn Fredericks, shows 'The Hartgers View', the earliest known depiction of New Amsterdam, as it appeared in the 1620s. Photograph by Lebrecht History/Bridgeman Images So during the 1960s and 1970s, U.S. university researchers made new attempts to identify this shipwreck. Rather than clarifying the matter, those investigations only deepened the Tyger's enigma. One analysis concluded the Tyger might not have burned fully, and its materials may have been salvaged to build Block's replacement ship. Other studies suggested those remains could have been stolen by looters during the 1900s. Or that they are sitting in a museum storage facility somewhere in the U.S. just waiting to be rediscovered. Now, however, the MCNY hopes it can solve this puzzle by testing the shipwreck remains uncovered in 1916, says McQuade. Although the museum has held these artifacts for eight decades, this will be its most comprehensive investigation into their origins. Previous studies of the timber did not utilize tree ring pattern analysis. Also called dendrochronology, this is one of several scientific tools which may be used during the MCNY study, says McQuade. Dendrochronology lets researchers determine when and where a piece of timber was cut. Species identification, meanwhile, can reveal the type of tree a piece of timber came from. And isotopic analysis, which is also being considered by MCNY, studies chemical signatures in the wood to pinpoint its geographic origin. This shipwreck investigation is the museum's landmark project to mark New York's 400th anniversary, explains Wilchfort. 'Depending on the findings, they could be used in multiple future installations, including our permanent exhibition, New York at Its Core, the city's largest interactive timeline,' she says. For now, however, the mystery persists of which ship—the Tyger? Or another unknown vessel?—lurked for centuries beneath what would become one of the busiest places on earth, just waiting to be discovered and deciphered.
Business Wire
6 hours ago
- Business Wire
Samsung Bioepis' European Whitepaper Proposes Solutions to Bridge Policy Gaps that Hinder Healthy Market Competition and Timely Access to Biosimilar Medicines
INCHEON, Korea--(BUSINESS WIRE)--Samsung Bioepis Co., Ltd. today published a whitepaper titled ' Solving the Biosimilar Void in Europe ' that proposes policy recommendations to fully recognize the value of biosimilars and ensure a more sustainable market in Europe. Policies should take a patient-centric approach, positioning biosimilars as part of the solution to expand access, improve patient outcomes, ensure supply continuity, and strengthen system resilience. Share Biosimilars have played a significant role in alleviating the financial burden on the European healthcare system, having delivered €56 billion in cumulative cost savings across Europe over the past 11 years (2013-2024). 1 However, the current policy environment in Europe, particularly the post-launch pathways, is misaligned to incentivize biosimilar competition. With post-marketing challenges, on top of high development costs, many biologics will not face biosimilar competition at the point of loss of exclusivity (LoE) within the next decade. The whitepaper proposes several measures to improve current practices that hinder healthy market competition and timely access to biosimilar medicines: Health Technology Assessment (HTA) needs to be tailored for biosimilars: With its origin in innovative medicine, HTA is a multidisciplinary process that evaluates the medical, social, economic, and ethical implications of health technologies. Some countries often have oversimplified HTA requirements for biosimilars, where reimbursement decisions are solely based on price comparisons and do not take into account biosimilars' additional benefits or where the reference biologic is not reimbursed. In many cases, HTA is relevant, but with limited guidance to properly assess the biosimilar's value. HTA can be more streamlined and tailored to speed up the entry of biosimilars to the market. In some countries, pricing and reimbursement (P&R) policies focus on achieving the lowest possible prices through mechanisms such as price linkage and reference pricing, thereby accelerating price erosion: Out of 28 European countries, 12 countries use external reference pricing methods and 17 countries mandate arbitrary discounts on biosimilar prices at an average of 28% below reference product. 2 Already set at significantly lower levels, biosimilar prices are driven further downward as competition begins, often leading to price erosion that drives players out of the market. Instead of arbitrary price-controls, free pricing will allow price discounts to be achieved naturally through free competition. Tenders often favor a single-winner system and tend to overlook broader qualitative factors such as supply stability and quality assurance: National, regional, and local tenders should support supply diversification and fair competition through multi-winner systems, with greater transparency in communication and more periodic tender reopenings so that late entrants are also given opportunities to participate. Security and stability of supply should be given higher priority in tenders to enhance demand predictability and incentivize manufacturers to secure more robust supply chains. Biosimilar uptake cannot be achieved without the support of physicians and pharmacists who prescribe and dispense these medicines: Incentives extended to healthcare professionals to encourage the prescribing and dispensing of biosimilars vary significantly across European countries. In some countries, prescriber incentives are misaligned, discouraging the use of biosimilar medicines. Incentive programs should be based on shared decision-making between physicians and patients, rather than automatic switching. Gainsharing can be introduced to stimulate biosimilar uptake while preserving competition and autonomy. Education programs for physicians, pharmacists, and patients should be continued to support wider use of biosimilars. 'Biosimilars are not one-size-fits-all, and establishing a sustainable framework for biosimilars requires a nuanced understanding of their heterogeneous applications across clinical settings. It is vital to tailor key solutions that address the unique challenges faced by different product types, prescribing patterns, and patient and disease characteristics. It is also important to consider the future viability of the market when reshaping policies, as the market needs clear signals of long-term sustainability to encourage continued investments in the biosimilar pipeline,' said Adam Levysohn, Vice President and Head of Commercial Strategy Europe, at Samsung Bioepis. 'It is important for healthcare systems to recognize that biosimilars are not merely a cost-saving tool for organizations. Policies should take a patient-centric approach, positioning biosimilars as part of the solution to expand access, improve patient outcomes, ensure supply continuity, and strengthen system resilience.' Samsung Bioepis is a biopharmaceutical company that develops and manufactures high-quality biosimilars to accelerate patient access to biologic medicines. As a world leader in biosimilars, Samsung Bioepis has a broad pipeline of biosimilar candidates that cover a spectrum of therapeutic areas, including immunology, oncology, ophthalmology, hematology, nephrology, and endocrinology. Of the 11 biosimilars approved worldwide, eight products are available across Europe. To access the report Solving the Biosimilar Void in Europe, please visit HERE. About Samsung Bioepis Co., Ltd. Established in 2012, Samsung Bioepis is a biopharmaceutical company committed to realizing healthcare that is accessible to everyone. Through innovations in product development and a firm commitment to quality, Samsung Bioepis aims to become the world's leading biopharmaceutical company. Samsung Bioepis continues to advance a broad pipeline of biosimilar candidates that cover a spectrum of therapeutic areas, including immunology, oncology, ophthalmology, hematology, nephrology, and endocrinology. For more information, please visit: and follow us on social media – LinkedIn, X.
Yahoo
12 hours ago
- Yahoo
CARsgen Successfully Defends Its GPC3 CAR-T Patent at the EPO
SHANGHAI, July 13, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: a company focused on developing innovative CAR T-cell therapies, announces a favorable outcome in opposition proceedings before the European Patent Office (EPO) concerning its European patent EP3445407, which covers its GPC3-targeted CAR-T cell therapy. On July 3, 2025, a U.S.-based biotechnology — the sole appellant among the original two opponents — formally withdrew its appeal against the EPO Opposition Division's earlier decision to maintain the patent. This withdrawal renders the EPO's decision final and binding for the opponents, effectively concluding their part in the opposition process. The patent was granted by the EPO in 2022 and opposed by two parties in 2023. Following oral proceedings, the EPO Opposition Division issued a decision to maintain the patent in amended form, upholding key claims related to the use of GPC3 CAR-T cell therapy following cyclophosphamide and fludarabine lymphodepletion pretreatment, in the treatment of liver cancer, lung cancer, ovarian cancer, breast cancer, gastric cancer, and thyroid cancer. Following the decision, only one opponent filed an appeal within the allowable period. That appeal has now been withdrawn. Under EPO procedures, the opponents or any other third party can no longer challenge the patent at the EPO. This development further reinforces CARsgen's intellectual property position in the field of GPC3-targeted CAR-T therapies, a promising and innovative approach for the treatment of solid tumors. About CARsgen Therapeutics Holdings Limited CARsgen is a biopharmaceutical company focusing on developing innovative CAR T-cell therapies to address the unmet clinical needs including but not limited to hematologic malignancies, solid tumors and autoimmune diseases. CARsgen has established end-to-end capabilities for CAR T-cell research and development covering target discovery, preclinical research, product clinical development, and commercial-scale production. CARsgen has developed novel in-house technologies and a product pipeline with global rights to address challenges faced by existing CAR T-cell therapies. Efforts include improving safety profile, enhancing the efficacy in treating solid tumors, and reducing treatment costs, etc. CARsgen's mission is to be a global biopharmaceutical leader that provides innovative and differentiated cell therapies for patients worldwide and makes cancer and other diseases curable. Forward-looking Statements All statements in this press release that are not historical fact or that do not relate to present facts or current conditions are forward-looking statements. Such forward-looking statements express the Group's current views, projections, beliefs and expectations with respect to future events as of the date of this press release. Such forward-looking statements are based on a number of assumptions and factors beyond the Group's control. As a result, they are subject to significant risks and uncertainties, and actual events or results may differ materially from these forward-looking statements and the forward-looking events discussed in this press release might not occur. Such risks and uncertainties include, but are not limited to, those detailed under the heading "Principal Risks and Uncertainties" in our most recent annual report and interim report and other announcements and reports made available on our corporate website, No representation or warranty is given as to the achievement or reasonableness of, and no reliance should be placed on, any projections, targets, estimates or forecasts contained in this press release. Contact CARsgen For more information, please visit View original content to download multimedia: SOURCE CARsgen Therapeutics
